View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
February 28, 2019

Innovent begins Tyvyt dosing in liver cancer patients

Innovent Biologics has commenced dosing in the Phase II/III ORIENT-32 clinical trial of its Tyvyt (sintilimab injection) plus IBI305 combination as first-line therapy for advanced hepatocellular carcinoma (HCC), a common type of liver cancer.

Innovent Biologics has commenced dosing in the Phase II/III ORIENT-32 clinical trial of its Tyvyt (sintilimab injection) plus IBI305 combination as first-line therapy for advanced hepatocellular carcinoma (HCC), a common type of liver cancer.

Tyvyt is a fully human anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody.

IBI305 is a recombinant humanised monoclonal antibody and a biosimilar candidate of bevacizumab that targets vascular endothelial growth factor (VEGF).

The randomised, open-label, multi-centre ORIENT-32 trial is designed to assess the safety and efficacy of the combination therapy, compared to sorafenib, in 566 participants.

The primary endpoint of the trial is overall survival, while the primary outcome measures also include objective response rate.

“The development of new agents for the treatment of advanced HCC has been stagnant, so there is a huge unmet clinical need.”

Second outcome measures are disease control rate, duration of response, time to progression, progression-free survival and time to response.

Innovent Biologics founder, CEO and chairman Michael Yu said: “The development of new agents for the treatment of advanced HCC has been stagnant, so there is a huge unmet clinical need.

“Based on the encouraging data we have observed in our Phase Ib study, we have decided to conduct the ORIENT-32 trial, a Phase II/III study in first-line advanced HCC.”

Innovent is developing Tyvyt in China in alliance with Eli Lilly. Sintilimab injection is currently undergoing 20 clinical studies for a variety of solid tumours.

The therapeutic received marketing approval from the National Medical Products Administration (NMPA) in China for treating relapsed or refractory classical Hodgkin’s lymphoma (r/r cHL).

Innovent announced acceptance of IBI305’s new drug application (NDA) last month.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena